HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Recombinant snake venom cystatin inhibits tumor angiogenesis in vitro and in vivo associated with downregulation of VEGF-A165, Flt-1 and bFGF.

Abstract
Previous studies have shown that recombinant snake venom cystatin (sv-cystatin) inhibits the invasion and metastasis of tumor cells in vitro and in vivo. The purpose of this study was to investigate the ability of recombinant sv-cystatin to inhibit tumor angiogenesis in vitro and in vivo, and the mechanisms underlying this effect. Recombinant sv-cystatin inhibited proliferation of human umbilical vein endothelial cells (HUVECs) at 100 and 200 μg/mL after 72, 96 and 120 h. Recombinant sv-cystatin also inhibited tumor-endothelial cell adhesion at 25, 50, 100 and 200 μg/mL. Recombinant sv-cystatin inhibited capillary-like tube formation by HUVECs at 10, 25, 50, 100 and 200 μg/mL following 12, 24 and 36 h incubation. Furthermore, recombinant sv-cystatin significantly suppressed microvessel density (MVD) of lung tumor colonies in C57BL/6 mice inoculated in the lateral tail vein with B16F10 melanoma cells. Administration of recombinant sv-cystatin significantly decreased MVD of primary tumor tissues in nude mice implanted subcutaneously with human hepatocellular carcinoma cells (MHCC97H). Exposure of B16F10 and MHCC97H cells to increasing doses of recombinant sv-cystatin suppressed secretion of vascular endothelial growth factor (VEGF)-A165 and basic fibroblast growth factor (bFGF) into the surrounding medium (P < 0.05). The expression of fms-related tyrosine kinase 1 (Flt-1) protein in HUVECs was decreased by 25, 50, 100 and 200 μg/mL recombinant sv-cystatin (P < 0.05). This study demonstrates that recombinant sv-cystatin inhibits tumor angiogenesis associated with downregulation of VEGF-A165, Flt-1 and bFGF. This suggests that recombinant sv-cystatin may have potential pharmaceutical applications as an antiangiogenic and antimetastatic therapeutic agent.
AuthorsQun Xie, Nanhong Tang, Rong Wan, Yuanlin Qi, Xu Lin, Jianyin Lin
JournalAnti-cancer agents in medicinal chemistry (Anticancer Agents Med Chem) Vol. 13 Issue 4 Pg. 663-71 (May 2013) ISSN: 1875-5992 [Electronic] Netherlands
PMID23094915 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Cystatins
  • Recombinant Proteins
  • Snake Venoms
  • Vascular Endothelial Growth Factor A
  • Fibroblast Growth Factor 2
  • FLT1 protein, human
  • Vascular Endothelial Growth Factor Receptor-1
Topics
  • Animals
  • Cell Proliferation
  • Cystatins (chemistry, isolation & purification, metabolism)
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Fibroblast Growth Factor 2 (metabolism)
  • Human Umbilical Vein Endothelial Cells (cytology)
  • Humans
  • Mice
  • Mice, Inbred C57BL
  • Mice, Nude
  • Neoplasms, Experimental (metabolism)
  • Neovascularization, Pathologic (metabolism)
  • Recombinant Proteins
  • Snake Venoms (chemistry, isolation & purification, metabolism)
  • Structure-Activity Relationship
  • Tumor Cells, Cultured
  • Vascular Endothelial Growth Factor A (metabolism)
  • Vascular Endothelial Growth Factor Receptor-1 (metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: